Juvenile Inflammatory Rheumatism (JIR) Cohorte

Condition(s) studied

Study summary

The investigators created a cohort of patients with juvenile inflammatory rheumatisms with the purpose to follow them prospectively, and investigate the tolerance and efficacy of immunosuppresive and biological agents.

Eligibility

Primary outcome measure(s)

• Number of severe and very severe adverse event as a mesure of safety and tolerability — 10 years
• Number of treatments prescribed off label — 10 Years
• Length in months of drug survival in patient treated with at least two consecutive biological agents — 10 Years

Trial sites (45)

+ 5 more sites — see the full list on the official registry below.